Target intelligence / Profile preview

Multidrug efflux pump subunit AcrB (AcrB)

Target
AcrB
Molecular classification
Transporter, Resistance-Nodulation-Division (RND) family, Inner membrane protein
01

Overview

The Multidrug efflux pump subunit AcrB is the essential inner membrane component of the AcrAB-TolC system, the primary multidrug efflux pump in Gram-negative bacteria such as Escherichia coli (UniProt Consortium, 2023). It belongs to the Resistance-Nodulation-Division (RND) family and functions as a proton-motive force-dependent transporter that actively expels a wide variety of toxic compounds, including antibiotics, detergents, and dyes (Nikaido & Takatsuka, 2009). AcrB operates as a homotrimer, where each monomer cycles through three distinct conformational states—access, binding, and extrusion—to facilitate the peristaltic movement of substrates from the periplasm to the TolC exit duct (Yamaguchi et al., 2015). This efflux activity is a major driver of clinical multidrug resistance, as it prevents antibiotics like fluoroquinolones and beta-lactams from reaching their intracellular targets (Venter et al., 2015). Consequently, AcrB is a high-priority target for the development of efflux pump inhibitors (EPIs) like PAβN and D13-9001, which aim to restore antibiotic susceptibility (Nakashima et al., 2013). However, the development of these inhibitors faces challenges such as potential toxicity to host cells and the need for high potency to overcome the pump's high capacity (Opperman & Nguyen, 2015).

Other names
Acriflavine resistance protein BMultidrug transporter AcrBRND-type efflux pump AcrB
02

Mechanism of action

Efflux pump inhibition (EPI)

03

Biological functions

Multidrug effluxProton-motive force-driven transportAntibiotic resistanceXenobiotic transportMaintenance of cell envelope integrity
04

Disease associations

Bacterial infectionMultidrug resistance (MDR)
05

Safety considerations

Potential mammalian cell toxicityOff-target inhibition of human transporters (e.g., P-glycoprotein)Pharmacokinetic and pharmacodynamic challenges in clinical developmentSelection for compensatory resistance mutations
06

Interacting drugs

Phenyl-arginine-beta-naphthylamide (PAβN)

4 more in the full profile.

07

Biomarkers

AcrB mRNA expression levelsAcrB protein levelsMinimum Inhibitory Concentration (MIC) reduction in the presence of efflux pump inhibitors

Beyond the preview

Go deeper on Multidrug efflux pump subunit AcrB (AcrB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Multidrug efflux pump subunit AcrB (AcrB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call